Cue Biopharma Inc Ordinary Shares CUE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Cue Biopharma Announces Pricing of $12.0 Million Public Offering
-
Cue Biopharma Announces Proposed Public Offering
-
Cue Biopharma Announces Proposed Public Offering
-
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
-
Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
-
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
-
Cue Biopharma to Host Business Update Call and Webcast
-
Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
Trading Information
- Previous Close Price
- $0.68
- Day Range
- $0.68–0.77
- 52-Week Range
- $0.45–3.25
- Bid/Ask
- $0.74 / $0.77
- Market Cap
- $36.83 Mil
- Volume/Avg
- 1.5 Mil / 488,397
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.96
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 53
- Website
- https://www.cuebiopharma.com
Comparables
Valuation
|
Metric
|
CUE
|
PRLD
|
CELC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.53 | 0.64 | 3.02 |
Price/Sales | 3.96 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
CUE
PRLD
CELC
Financial Strength
|
Metric
|
CUE
|
PRLD
|
CELC
|
|---|---|---|---|
Quick Ratio | 1.94 | 7.71 | 14.50 |
Current Ratio | 2.06 | 7.83 | 14.95 |
Interest Coverage | −38.67 | — | −13.28 |
Quick Ratio
CUE
PRLD
CELC
Profitability
|
Metric
|
CUE
|
PRLD
|
CELC
|
|---|---|---|---|
Return on Assets (Normalized) | −64.95% | −40.98% | −39.76% |
Return on Equity (Normalized) | −109.77% | −46.70% | −58.91% |
Return on Invested Capital (Normalized) | −80.34% | −44.57% | −44.39% |
Return on Assets
CUE
PRLD
CELC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Gfdvbtqbd | Njsnv | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Xmwbnqyy | Kzkzqr | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xlnxfnpb | Xnvpc | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wlklxxlcj | Fgsrrn | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Qhmmmqpk | Hqfs | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Qzlwpvlpc | Xzcy | $28.1 Bil | |||
| Moderna Inc
MRNA
| Qcjpywnp | Ztvs | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Dbhcwrlsz | Qyfqt | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Fmjkhbvn | Jbmtdp | $13.4 Bil | |||
| Incyte Corp
INCY
| Dcjvnxmqs | Gfdqczj | $12.7 Bil |
United States